BC Innovations | Jan 18, 2018
Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
BC Week In Review | Jul 14, 2017
Company News

Eisai grants 2XOncology rights to 2X-121

Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan  2X Oncology Inc. , Cambridge, Mass.  Business: Cancer  Eisai Co. Ltd. (Tokyo:4523) granted 2X Oncology Inc. (Cambridge, Mass.) exclusive, worldwide rights to develop and commercialize cancer candidate 2X-121 (previously E7449)....
Items per page:
1 - 2 of 2